
## Imperial College London

Department of Oncology Division of Surgery, Oncology, Reproductive Medicine and Anaesthetics (SORA) Imperial College London



10<sup>th</sup> January 2006



Jonathan Waxman Professor of Oncology

Professor David Barnett
Chair, Appraisal Committee
NICE
c/o Alana Miller
Technology Appraisal Project Manager
MidCity Place
71 High Holborn
LONDON WC1V 6NA

Dear Professor Barnett,

David

Re: Docetaxel for prostate cancer

You have asked for responses to the Appraisal Consultation Document. I was very impressed with the thoroughness and quality of the review, and was pleased to note that the committee has recommended the use of docetaxel for fit patients who have recurrent prostate cancer.

With kind regards,

Yours sincerely,

